Finally, non-small cell lung carcinoma (NSCLC) is less sensitive to cisplatin when IL-6 produced by CAFs stimulates well-studied pro-survival signalling cascades and enhances TGF-β1-driven EMT in lung cancer cells [59]. Here, IL6 is linked to non-small cell lung carcinoma.